Lantern Pharma’s LP-184 delivered promising anti-tumor activity with 48% disease control and strongest responses in patients with DNA damage response mutations (CHK2, ATM, BRCA1, STK11/KEAP1). Using its RADR® AI platform, Lantern identified top responder groups and prioritized Phase Ib/II trials in triple-negative breast cancer TNBC (with Lynparza), NSCLC (± immunotherapy), and bladder cancer with DDR alterations.
